Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors

Biomaterials

Volumn 34, Issue 36, 2013, Pages 9201-9209

  Brudno, Yevgeny ^a,b   Ennett Shepard, Alessandra B ^a,c   Chen, Ruth R ^a,c   Aizenberg, Michael ^b   Mooney, David J ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Angiogenesis; Controlled drug release; Drug delivery; Endothelial cell; Growth factors; Smooth muscle cell

Indexed keywords

ANGIOGENESIS; CONTROLLED DRUG RELEASE; GROWTH FACTOR; PERIPHERAL ARTERY DISEASE; PLATELET-DERIVED GROWTH FACTORS; SMOOTH MUSCLE CELLS; TISSUE ENGINEERED CONSTRUCTS; VASCULAR ENDOTHELIAL GROWTH FACTOR;

DISEASES; DRUG DELIVERY; ENDOTHELIAL CELLS; PATIENT TREATMENT;

BLOOD VESSELS;

ANGIOPOIETIN 1; ANGIOPOIETIN 2; GROWTH FACTOR; MICROSPHERE; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; POLYMER; SCAFFOLD PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CAPILLARY DENSITY; CELL ADHESION; COCULTURE; CONTROLLED STUDY; DIABETIC FOOT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PERICYTE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; SPROUTING; VASCULARIZATION; WOUND HEALING;

ANGIOGENESIS; CONTROLLED DRUG RELEASE; DRUG DELIVERY; ENDOTHELIAL CELL; GROWTH FACTORS; SMOOTH MUSCLE CELL;

ANGIOGENESIS INDUCING AGENTS; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; ANTIGENS, CD31; ENDOTHELIUM, VASCULAR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICROVESSELS; NEOVASCULARIZATION, PHYSIOLOGIC; PERICYTES; PLATELET-DERIVED GROWTH FACTOR; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84883780219     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.08.007     Document Type: Article

References (65)

1. Attanasio S., Snell J. Therapeutic angiogenesis in the management of critical limb ischemia: current concepts and review. Cardiol Rev 2009, 17:115-120.
2. Freedman S., Isner J. Therapeutic angiogenesis for ischemic cardiovascular disease. JMol Cell Cardiol 2001, 33:379-393.
3. Losordo D., Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation 2004, 109:2692-2697.
4. Silva E., Mooney D. Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. JThromb Haemost 2007, 5:590-598.
5. Silva E., Mooney D. Effects of VEGF temporal and spatial presentation on angiogenesis. Biomaterials 2010, 31:1235-1241.
6. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6:389-395.
7. Jain R. Molecular regulation of vessel maturation. Nat Med 2003, 9:685-693.
8. Chu H., Wang Y. Therapeutic angiogenesis: controlled delivery of angiogenic factors. Ther Deliv 2012, 3:693-714.
9. Conway E., Collen D., Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001, 49:507-521.
10. Jain R. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
11. Vailhé B., Vittet D., Feige J. Invitro models of vasculogenesis and angiogenesis. Lab Invest 2001, 81:439-452.
12. Cao L., Arany P., Kim J., Rivera-Feliciano J., Wang Y.-S., He Z., et al. Modulating notch signaling to enhance neovascularization and reperfusion in diabetic mice. Biomaterials 2010, 31:9048-9056.
13. Cao L., Arany P., Wang Y.-S., Mooney D. Promoting angiogenesis via manipulation of VEGF responsiveness with notch signaling. Biomaterials 2009, 30:4085-4093.
14. Cao L., Mooney D. Spatiotemporal control over growth factor signaling for therapeutic neovascularization. Adv Drug Deliv Rev 2007, 59:1340-1350.
15. Chen R., Silva E., Yuen W., Mooney D. Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res 2007, 24:258-264.
16. Yung Y., Chae J., Buehler M., Hunter C., Mooney D. Cyclic tensile strain triggers asequence of autocrine and paracrine signaling to regulate angiogenic sprouting in human vascular cells. Proc Natl Acad Sci U S A 2009, 106:15279-15284.
17. Tremblay P.-L., Berthod F., Germain L., Auger F. Invitro evaluation of the angiostatic potential of drugs using an endothelialized tissue-engineered connective tissue. JPharmacol Exp Ther 2005, 315:510-516.
18. Clapp C., Martial J., Guzman R., Rentier-Delure F., Weiner R. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993, 133:1292-1299.
19. Yuen W., Du N., Chan C., Silva E., Mooney D. Mimicking nature by codelivery of stimulant and inhibitor to create temporally stable and spatially restricted angiogenic zones. Proc Natl Acad Sci U S A 2010, 107:17933-17938.
20. Pelletier L., Regnard J., Fellmann D., Charbord P. An invitro model for the study of human bone marrow angiogenesis: role of hematopoietic cytokines. Lab Invest 2000, 80:501-511.
21. Korff T., Kimmina S., Martiny-Baron G., Augustin H. Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness. FASEB J 2001, 15:447-457.
22. Orlidge A., D'Amore P. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. JCell Biol 1987, 105:1455-1462.
23. Hellström M., Gerhardt H., Kalén M., Li X., Eriksson U., Wolburg H., et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. JCell Biol 2001, 153:543-553.
24. Herman I., D'Amore P. Microvascular pericytes contain muscle and nonmuscle actins. JCell Biol 1985, 101:43-52.
25. Peppiatt C., Howarth C., Mobbs P., Attwell D. Bidirectional control of CNS capillary diameter by pericytes. Nature 2006, 443:700-704.
26. Yemisci M., Gursoy-Ozdemir Y., Vural A., Can A., Topalkara K., Dalkara T. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat Med 2009, 15:1031-1037.
27. Kutcher M., Herman I. The pericyte: cellular regulator of microvascular blood flow. Microvasc Res 2009, 77:235-246.
28. Antonelli-Orlidge A., Smith S., D'Amore P. Influence of pericytes on capillary endothelial cell growth. Am Rev Respir Dis 1989, 140:1129-1131.
29. Darland D., Massingham L., Smith S., Piek E., Saint-Geniez M., D'Amore P. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 2003, 264:275-288.
30. Song S., Ewald A., Stallcup W., Werb Z., Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005, 7:870-879.
31. Gerhardt H., Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003, 314:15-23.
32. Borselli C., Storrie H., Benesch-Lee F., Shvartsman D., Cezar C., Lichtman J., et al. Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors. Proc Natl Acad Sci U S A 2010, 107:3287-3292.
33. Borselli C., Cezar C., Shvartsman D., Vandenburgh H., Mooney D. The role of multifunctional delivery scaffold in the ability of cultured myoblasts to promote muscle regeneration. Biomaterials 2011, 32:8905-8914.
34. Lutton C., Young Y., Williams R., Meedeniya A., Mackay-Sim A., Goss B. Combined VEGF and PDGF treatment reduces secondary degeneration after spinal cord injury. JNeurotrauma 2012, 29:957-970.
35. Reyes R., De la Riva B., Delgado A., Hernández A., Sánchez E., Évora C. Effect of triple growth factor controlled delivery by a brushite-PLGA system on a bone defect. Injury 2012, 43:334-342.
36. Richardson T., Peters M., Ennett A., Mooney D. Polymeric system for dual growth factor delivery. Nat Biotechnol 2001, 19:1029-1034.
37. Cao R., Bråkenhielm E., Pawliuk R., Wariaro D., Post M., Wahlberg E., et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003, 9:604-613.
38. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999, 237:1-30.
39. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000, 11:617-624.
40. Davies N., Schmidt C., Bezuidenhout D., Zilla P. Sustaining neovascularization of a scaffold through staged release of vascular endothelial growth factor-A and platelet-derived growth factor-BB. Tissue Eng Part A 2012, 18:26-34.
41. Goel S., Duda D., Xu L., Munn L., Boucher Y., Fukumura D., et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91:1071-1121.
42. Darland D., D'Amore P. Blood vessel maturation: vascular development comes of age. JClin Invest 1999, 103:157-158.
43. Abramsson A., Lindblom P., Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. JClin Invest 2003, 112:1142-1151.
44. Song N., Huang Y., Shi H., Yuan S., Ding Y., Song X., et al. Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/CXCR4 axis. Cancer Res 2009, 69:6057-6064.
45. Hellström M., Kalén M., Lindahl P., Abramsson A., Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999, 126:3047-3055.
46. Davis S., Yancopoulos G. The angiopoietins: Yin and Yang in angiogenesis. Curr Top Microbiol Immunol 1999, 237:173-185.
47. Gale N., Yancopoulos G. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999, 13:1055-1066.
48. Maisonpierre P., Suri C., Jones P., Bartunkova S., Wiegand S., Radziejewski C., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts invivo angiogenesis. Science 1997, 277:55-60.
49. Greenberg J., Shields D., Barillas S., Acevedo L., Murphy E., Huang J., et al. Arole for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456:809-813.
50. Edelman E., Mathiowitz E., Langer R., Klagsbrun M. Controlled and modulated release of basic fibroblast growth factor. Biomaterials 1991, 12:619-626.
51. Gombotz W., Pettit D. Biodegradable polymers for protein and peptide drug delivery. Bioconjug Chem 1995, 6:332-351.
52. Kuo P., Saltzman W. Novel systems for controlled delivery of macromolecules. Crit Rev Eukaryot Gene Expr 1996, 6:59-73.
53. Langer R. Drug delivery and targeting. Nature 1998, 392:5-10.
54. Lee K., Peters M., Anderson K., Mooney D. Controlled growth factor release from synthetic extracellular matrices. Nature 2000, 408:998-1000.
55. Mahoney M., Saltzman W. Millimeter-scale positioning of a nerve-growth-factor source and biological activity in the brain. Proc Natl Acad Sci U S A 1999, 96:4536-4539.
56. Murray J., Brown L., Langer R. Controlled release of microquantities of macromolecules. Cancer Drug Deliv 1984, 1:119-123.
57. Peirce S., Price R., Skalak T. Spatial and temporal control of angiogenesis and arterialization using focal applications of VEGF164 and Ang-1. Am J Physiol Heart Circ Physiol 2004, 286:25.
58. Ennett A., Kaigler D., Mooney D. Temporally regulated delivery of VEGF invitro and invivo. JBiomed Mater Res A 2006, 79:176-184.
59. Benjamin L., Hemo I., Keshet E. Aplasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998, 125:1591-1598.
60. Roviezzo F., Tsigkos S., Kotanidou A., Bucci M., Brancaleone V., Cirino G., et al. Angiopoietin-2 causes inflammation invivo by promoting vascular leakage. JPharmacol Exp Ther 2005, 314:738-744.
61. Scharpfenecker M., Fiedler U., Reiss Y., Augustin H. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. JCell Sci 2005, 118:771-780.
62. Yoshiji H., Kuriyama S., Noguchi R., Yoshii J., Ikenaka Y., Yanase K., et al. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut 2005, 54:1768-1775.
63. Hori S., Ohtsuki S., Hosoya K.-i., Nakashima E., Terasaki T. Apericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation invitro. JNeurochem 2004, 89:503-513.
64. Sundberg C., Kowanetz M., Brown L., Detmar M., Dvorak H. Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis invivo. Lab Invest 2002, 82:387-401.
65. Uemura A., Ogawa M., Hirashima M., Fujiwara T., Koyama S., Takagi H., et al. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. JClin Invest 2002, 110:1619-1628.